Skip to main content
Premium Trial:

Request an Annual Quote

Sensible Diagnostics Nabs RADx Award of up to $1M for Respiratory Panel

NEW YORK – Point-of-care molecular diagnostics firm Sensible Diagnostics said Tuesday that it will receive up to $1 million in funding from the National Institutes of Health for the development, commercialization, and implementation of a multiplex test for COVID-19 and influenza A/B.

Los Angeles-based Sensible said it will receive the milestone-based funding within the next four months from the NIH's Rapid Acceleration of Diagnostics (RADx) Tech program. The firm will use the money to accelerate its development of a PCR-based multiplex point-of-care respiratory panel for differentiating SARS-CoV-2 and influenza A/B infections.

The company is developing a test that can be performed in 10-15 minutes that it said will cost the same or less than current molecular tests and CLIA-waived antigen tests.

Sensible said it is also developing a separate test for group A Streptococcus, and it plans to develop additional tests for sexually transmitted infections including hepatitis C and HIV infections as well as a panel to screen newborns for infectious diseases.

Curative spun off Sensible Diagnostics as a standalone company in April. It said at the time the company was developing a 10-minute point-of-care PCR testing platform called the Sensible Platform. Sensible said the Curative engineers and scientists who developed the platform also performed more than 200,000 COVID-19 tests daily during the height of the pandemic, which gives Sensible Diagnostics unique insights about the accuracy, speed, and costs of testing required by healthcare providers.

"As the only point-of-care system that was designed by people who have actually run point-of-care tests in the field, these funds will be put to use to further our mission of developing and commercializing one of the world's most affordable, accessible, and accurate point-of-care PCR testing platforms," Sensible CEO Ernest Templin said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.